Significant PFS Benefit for the Nivolumab + Relatlimab Combination for Patients with Unresectable or Metastatic Melanoma
The dual-checkpoint inhibitor combination of nivolumab and relatlimab continues to provide a significant efficacy benefit over nivolumab alone in patients with previously untreated unresectable or metastatic melanoma according to RELATIVITY-047 update.